Neisseria meningitidis Infections R&D Pipeline Analysis Report, Q4 2020
Neisseria meningitidis Infections Pipeline Overview
The Q4 Neisseria meningitidis Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Neisseria meningitidis Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Neisseria meningitidis Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Neisseria meningitidis Infections disease overview, Neisseria meningitidis Infections types, Neisseria meningitidis Infections symptoms, causes, and FDA/EMA approved treatment options.
Neisseria meningitidis Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Neisseria meningitidis Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Neisseria meningitidis Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 15 companies. Business profiles and contact details of the companies actively perusing Neisseria meningitidis Infections pipeline are assessed.
Neisseria meningitidis Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Neisseria meningitidis Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Neisseria meningitidis Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Neisseria meningitidis Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Neisseria meningitidis Infections Pipeline Market News and Developments during 2020
The Neisseria meningitidis Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Neisseria meningitidis Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Neisseria meningitidis Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Neisseria meningitidis Infections, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Neisseria meningitidis Infections Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Neisseria meningitidis Infections disease overview, Neisseria meningitidis Infections types, Neisseria meningitidis Infections symptoms, causes, and FDA/EMA approved treatment options.
Neisseria meningitidis Infections Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Neisseria meningitidis Infections indication. The report presents near-term and long-term pipeline development trends and potential insights.
Neisseria meningitidis Infections Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 15 companies. Business profiles and contact details of the companies actively perusing Neisseria meningitidis Infections pipeline are assessed.
Neisseria meningitidis Infections R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Neisseria meningitidis Infections discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Neisseria meningitidis Infections companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Neisseria meningitidis Infections pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Neisseria meningitidis Infections Pipeline Market News and Developments during 2020
The Neisseria meningitidis Infections industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Neisseria meningitidis Infections Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Neisseria meningitidis Infections pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 15 companies are included including Beijing Minhai Biotechnology Co Ltd, Bioworld Technologies , CanSino Biologics Inc, Chongqing Zhifei Biological Products Co Ltd, GlaxoSmithKline Plc, Hilleman Laboratories Pvt Ltd, ImmunoBiology Ltd, Johnson & Johnson, Neoculi Pty Ltd, Novo Medi Sciences Pvt Ltd, Omvax Inc, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Wellstat Vaccines LLC,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Neisseria meningitidis Infections pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Neisseria meningitidis Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Neisseria meningitidis Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Neisseria meningitidis Infections pipeline
2.5 Active Companies Developing Neisseria meningitidis Infections pipeline
3. NEISSERIA MENINGITIDIS INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Beijing Minhai Biotechnology Co Ltd
Bioworld Technologies
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
ImmunoBiology Ltd
Johnson & Johnson
Neoculi Pty Ltd
Novo Medi Sciences Pvt Ltd
Omvax Inc
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
5. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Neisseria meningitidis Infections Pipeline, 2020
2.2 Most focused Mechanism of Action in Neisseria meningitidis Infections Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Neisseria meningitidis Infections pipeline
2.5 Active Companies Developing Neisseria meningitidis Infections pipeline
3. NEISSERIA MENINGITIDIS INFECTIONS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Beijing Minhai Biotechnology Co Ltd
Bioworld Technologies
CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
GlaxoSmithKline Plc
Hilleman Laboratories Pvt Ltd
ImmunoBiology Ltd
Johnson & Johnson
Neoculi Pty Ltd
Novo Medi Sciences Pvt Ltd
Omvax Inc
Pfizer Inc
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
5. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
